Cargando…

From controlled opioid substitution treatment to pharmacy delivery of buprenorphine-naloxone and to treatment in primary health care: the views of patients and personnel

INTRODUCTION: There are 4000–5000 opioid abusers and about 1700 patients in opioid substitution treatment in Finland. New legislation (2008) allows less restrictive treatment models than before. AIMS: To assess advantages and disadvantages of pharmacy delivery of buprenorphine-naloxone and referral...

Descripción completa

Detalles Bibliográficos
Autores principales: Tourunen, Jouni, Pitkänen, Tuuli, Kaskela, Teemu
Formato: Texto
Lenguaje:English
Publicado: Igitur, Utrecht Publishing & Archiving 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3031843/
_version_ 1782197394818990080
author Tourunen, Jouni
Pitkänen, Tuuli
Kaskela, Teemu
author_facet Tourunen, Jouni
Pitkänen, Tuuli
Kaskela, Teemu
author_sort Tourunen, Jouni
collection PubMed
description INTRODUCTION: There are 4000–5000 opioid abusers and about 1700 patients in opioid substitution treatment in Finland. New legislation (2008) allows less restrictive treatment models than before. AIMS: To assess advantages and disadvantages of pharmacy delivery of buprenorphine-naloxone and referral of stabile patients into primary health care. THEORY AND METHODS: The setting was five Finnish outpatient clinics involved in treatment of opioid dependence in 2008–2009. Seventy-four patients (75% males, mean age 33, ½– 8 years in treatment) were interviewed. A questionnaire regarding the patients'´ situation was filled in by the nurses (n=166 patients). The view of personnel was studied in five group interviews (n=24) and through a questionnaire (n=36). Qualitative and quantitative methods were used. RESULTS: Most patients were unemployed, had psychiatric problems, and had heavy history of drug abuse. Transition to pharmacy delivery and to primary health care was more difficult and time-consuming than expected. This was due to patients' insistent personal need for psychosocial treatment or concerns of the personnel. Financial and organizational factors also played an important role. CONCLUSIONS: A variety of treatment models, careful evaluation of the patients’ situation, and training of personnel of clinics and health centres, and pharmacy staff is needed. Both patients and personnel were willing to move towards less restrictive models, if they were flexible enough.
format Text
id pubmed-3031843
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Igitur, Utrecht Publishing & Archiving
record_format MEDLINE/PubMed
spelling pubmed-30318432011-02-02 From controlled opioid substitution treatment to pharmacy delivery of buprenorphine-naloxone and to treatment in primary health care: the views of patients and personnel Tourunen, Jouni Pitkänen, Tuuli Kaskela, Teemu Int J Integr Care Conference Abstract INTRODUCTION: There are 4000–5000 opioid abusers and about 1700 patients in opioid substitution treatment in Finland. New legislation (2008) allows less restrictive treatment models than before. AIMS: To assess advantages and disadvantages of pharmacy delivery of buprenorphine-naloxone and referral of stabile patients into primary health care. THEORY AND METHODS: The setting was five Finnish outpatient clinics involved in treatment of opioid dependence in 2008–2009. Seventy-four patients (75% males, mean age 33, ½– 8 years in treatment) were interviewed. A questionnaire regarding the patients'´ situation was filled in by the nurses (n=166 patients). The view of personnel was studied in five group interviews (n=24) and through a questionnaire (n=36). Qualitative and quantitative methods were used. RESULTS: Most patients were unemployed, had psychiatric problems, and had heavy history of drug abuse. Transition to pharmacy delivery and to primary health care was more difficult and time-consuming than expected. This was due to patients' insistent personal need for psychosocial treatment or concerns of the personnel. Financial and organizational factors also played an important role. CONCLUSIONS: A variety of treatment models, careful evaluation of the patients’ situation, and training of personnel of clinics and health centres, and pharmacy staff is needed. Both patients and personnel were willing to move towards less restrictive models, if they were flexible enough. Igitur, Utrecht Publishing & Archiving 2010-12-06 /pmc/articles/PMC3031843/ Text en Copyright 2010, International Journal of Integrated Care (IJIC)
spellingShingle Conference Abstract
Tourunen, Jouni
Pitkänen, Tuuli
Kaskela, Teemu
From controlled opioid substitution treatment to pharmacy delivery of buprenorphine-naloxone and to treatment in primary health care: the views of patients and personnel
title From controlled opioid substitution treatment to pharmacy delivery of buprenorphine-naloxone and to treatment in primary health care: the views of patients and personnel
title_full From controlled opioid substitution treatment to pharmacy delivery of buprenorphine-naloxone and to treatment in primary health care: the views of patients and personnel
title_fullStr From controlled opioid substitution treatment to pharmacy delivery of buprenorphine-naloxone and to treatment in primary health care: the views of patients and personnel
title_full_unstemmed From controlled opioid substitution treatment to pharmacy delivery of buprenorphine-naloxone and to treatment in primary health care: the views of patients and personnel
title_short From controlled opioid substitution treatment to pharmacy delivery of buprenorphine-naloxone and to treatment in primary health care: the views of patients and personnel
title_sort from controlled opioid substitution treatment to pharmacy delivery of buprenorphine-naloxone and to treatment in primary health care: the views of patients and personnel
topic Conference Abstract
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3031843/
work_keys_str_mv AT tourunenjouni fromcontrolledopioidsubstitutiontreatmenttopharmacydeliveryofbuprenorphinenaloxoneandtotreatmentinprimaryhealthcaretheviewsofpatientsandpersonnel
AT pitkanentuuli fromcontrolledopioidsubstitutiontreatmenttopharmacydeliveryofbuprenorphinenaloxoneandtotreatmentinprimaryhealthcaretheviewsofpatientsandpersonnel
AT kaskelateemu fromcontrolledopioidsubstitutiontreatmenttopharmacydeliveryofbuprenorphinenaloxoneandtotreatmentinprimaryhealthcaretheviewsofpatientsandpersonnel